Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-07-05T08:24:05.376Z Has data issue: false hasContentIssue false

Buspirone in detoxification

Published online by Cambridge University Press:  02 January 2018

Raymond Travers*
Affiliation:
Regional Forensic Psychiatry Service, Scott Clinic Rainhill Hospital, Prescot, Merseyside
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Copyright
Copyright © The Royal College of Psychiatrists 

References

Eison, A. S., Eison, M. S., Riblet, L. A. et al (1983) Indications of serotonergic involvement in the actions of a potential non-benzodiazepine anxiolytic MJ 1385. Neuroscience Abstracts, 9, 436.Google Scholar
Gardner, M. J. & Altman, D. G. (1990). Confidence and clinical importance in research findings. British Journal of Psychiatry, 156, 472474.Google Scholar
Rickels, K., Case, W. G., Schweizer, E. G. et al (1986) Low dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients. Psychopharmacology Bulletin, 22, 407415.Google Scholar
Sanghera, M. K., McMillan, B. A. & German, D. C. (1985) Buspirone, a non-benzodiazepine anxiolytic, increases locus coerulus noradrenergic neuronal activity. European Journal of Pharmacology, 86, 107–100.Google Scholar
Schweizer, E. E., Amsterdam, J., Rickels, K., et al (1986) Open time of buspirone in the treatment of major depressive disorder. Psychopharmacology Bulletin, 22, 183185.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.